Glyburide nanosuspension: Influence of processing and formulation parameter on solubility and in vitro dissolution behavior
Main Article Content
Abstract
The nanosuspension is prepared by Top down technique, i.e. high pressure homogenization. The formulation factors which
affects particle size including concentration of surfactant while processing parameters includes homogenization pressure and
homogenization cycle. After particle size reduction, we observe that there are increases in the surface energy which requires
adequate stabilization by surfactant. In this study, practically water insoluble GB was nanoground and surfactant was employed
for their stabilizing effect. Inâ€vitro dissolution study revealed that increase in release rate of GB from nanoparticles (NPS) as
compare to pure raw GB. Field Emission Scanning Electron Microscope (FEâ€SEM) study showed the spherical morphology
of NPS. Particles size distribution, zeta potential, and crystal form of the formulated nanosuspension were studied by using
particle size analyzer and Xâ€ray powder diffraction. The result showed that the drug dissolution rate in nanosuspension
formulation is depending upon crystal form, solubility, preparation procedure, and stabilizer employed.
Key words: Bioavailability, Glyburide, high pressure homogenization, lyophilization, nanosuspension
Downloads
Article Details
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.
References
Dora CP, Singh SK, Kumar S, Datusalia AK, Deep A. Development
and characterization of nanoparticles of Glibenclamide by solvent
displacement method. Acta Pol Pharm 2010;67;283â€90.
Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug
formulations in therapy Rationale for development and what we can
expect for the future. Adv. Drug Deliv. Rev 2001;47:3â€19.
Davis SN, Granner DK. The pharmacological basis of therapeutics.
In: Hardman JG, Limbird LE, Gilman AG, editors. New York: McGrawâ€Hill;
p. 1679.
Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of
Nanosuspension for enhancing the dissolution of poorly soluble drugs.
Int J Pharm 2006;312:179â€86.
Tousif K, Mokale VJ. Nanosuspension: A novel approach for
enhancement of solubility and subsequent bioavailability. Inventi
Rapid:NDDS 2012:456 (4).
Naik JB, Mokale VJ. Formulation and evaluation of Repaglinide
nanoparticles as sustained release carriers. Int J Pharm Sci
;5:259â€66.
Cerdeira AM, Mazzotti M, Gander B, Miconazole Nanosuspension:
Influence of formulation variables on particle size reduction and
physical stability. Int J Pharm 2010;396:2010â€8.
Singh SK, Srinivasan KK, Singare DS, Investigation of preparation
parameters of Nanosuspension by topâ€down media milling to improve
the dissolution of poorly waterâ€soluble Glyburide. Eur J Pharm Biopharm
;78:441â€6.
Keck CM, Muller RH. Drug Nanocrystal of poorly soluble drugs
produced by high pressure homogenization. Eur J Pharm Biopharm
;62:3â€16.
Lai F, Sinico C, Ennas G, Marongiu F, Marongiu G, Fadda AM. Diclofenac
Nanosuspension: Influence of preparation procedure and crystal form
on drug dissolution behavior. Int J. Pharm 2009;373:124â€32.
USPâ€NF 2007: The Official Compendia of Standards; The Dissolution
Procedure: Development and Validation. USP 30/NF 25; 1092.